NSAID Rimifin Gets A New Taste

Pet owner compliance is critical to ensuring effective and continuing treatment in chronic conditions such as osteoarthritis. To help increase compliance, Rimifin, a NSAID marketed by Vetoquinol, has now got a new flavouring. Robert Simpson, Product Manager for Rimifin comments, “Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting. The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets.” To find out more about Rimifin please contact your Vetoquinol Territory Manager or call 01280 825424. Rimifin is a non-steroidal anti-inflammatory drug (NSAID) which contains carprofen (POM-V). For further information on Rimifin please contact Vetoquinol directly.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause